Oppenheimer Maintains Their Buy Rating on Personalis (PSNL)

By Carrie Williams

Oppenheimer analyst Kevin DeGeeter maintained a Buy rating on Personalis (PSNLResearch Report) yesterday and set a price target of $24.00. The company’s shares closed last Monday at $7.00, close to its 52-week low of $4.27.

According to TipRanks.com, DeGeeter is a 1-star analyst with an average return of -4.5% and a 35.9% success rate. DeGeeter covers the Healthcare sector, focusing on stocks such as Catalyst Biosciences, Molecular Templates, and Cidara Therapeutics.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Personalis with a $24.00 average price target.

See today’s analyst top recommended stocks >>

Based on Personalis’ latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $17.15 million and GAAP net loss of $6.89 million. In comparison, last year the company earned revenue of $11.65 million and had a GAAP net loss of $3.64 million.

Based on the recent corporate insider activity of 19 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of PSNL in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Personalis, Inc. provides genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. The company was founded by Euan A. Ashley, Michael Snyder, Atul J. Butte, John S. West, and Russ B. Altman in 2011 and is headquartered in Menlo Park, CA.